CTIS2022-503137-66-00进行中（未招募）1 期
A Phase 3b, multicenter, single-arm, open-label study evaluating the efficacy, safety, and tolerability of switching to DTG/3TC single tablet regimen administered once daily from a bictegravir/emtricitabine/tenofovir alafenamide single tablet regimen in people living with HIV of at least 50 years of age who are virologically suppressed - 219516
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age at least 50 years at the time of obtaining informed consent. Eligible participants must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrolment of participants who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures., Participants enrolled in France must be affiliated to, or a beneficiary of, a social security category., Male or female. Female participant is eligible to participate if she is not pregnant (as confirmed by a negative serum hCG test at Screening and a negative urine hCG test at Enrolment) and not lactating., Adults Living with HIV-1 with documented plasma HIV-1 RNA <50 c/mL within 3 months prior to Screening., Must have been on uninterrupted ART for =1 year (except for brief periods [less than 30 days] where all ART was stopped due to tolerability and/or safety concerns), Must be on uninterrupted BIC/FTC/TAF for at least 6 months prior to Screening, Plasma HIV-1 RNA <50 c/mL at Screening, No known prior regimen switches due to documented virologic failure (defined as a confirmed plasma HIV 1 RNA =200 c/mL), Participants with unknown full treatment/clinical history beyond 5 years prior to Screening may be eligible upon discussion and agreement with the medical monitor., Participant is capable of giving written informed consent
排除标准
- •Pregnant or breastfeeding women or those planning to become pregnant or breastfeed during the study, History or presence of allergy or intolerance to the study treatment, its components, drugs of their class, or other allergies that contraindicate participation., Ongoing malignancy other than cutaneous Kaposi’s sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia., Participants with significant suicidality risk, based on investigator judgment or history of suicidal behavior or ideation., Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of screening., Treatment with radiation therapy, cytotoxic chemotherapeutic agents, or systemic immune suppressants within 28 days of screening., Participants exposed to experimental drugs or vaccines within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent (whichever is longer, prior to the first dose of investigational product)., Anwendung eines Behandlungsschemas, das aus einer einzelnen oder einer dualen ART besteht, die in den Behandlungsleitlinien nicht empfohlen wird., Any known history of regimen switches due to virologic failure (confirmed plasma HIV 1 RNA =200 c/mL), Participants receiving protocol-defined prohibited medications who are unwilling or unable to switch to an alternate medication, Any evidence of any major 3TC resistance associated mutations (M184V/I and/or K65R and/or MDR) or presence of any major INSTI resistance associated mutation in any available prior resistance genotype assay test result., Active CDC Stage 3 disease is excluded, except for cutaneous Kaposi's sarcoma not needing systemic therapy. CD4 cell counts below 200 cells/mm3 (historical or current) are not exclusionary, Participants with verified Grade 4 laboratory abnormalities, except for Grade 4 lipid abnormalities., Alanine aminotransferase (ALT) levels =5 times the upper limit of normal (ULN) or ALT =3xULN with bilirubin =1.5xULN (with >35% direct bilirubin), Participants with estimated creatine clearance <30mL/min per 1.73 m2 using the refitted, race-neutral Chronic Kidney Disease Epidemiology Collaboration method, Participants currently or expected to participate in another interventional study after randomization, unless previously approved by the study medical monitor, Participants showing signs and symptoms suggestive of active SARS-CoV-2 infection within 14 days before enrolment, Participants with severe hepatic impairment (Class C) as per Child-Pugh classification., Evidence of hepatitis B virus (HBV) infection based on the results of testing at Screening: •Participants positive for hepatitis B surface antigen (HBsAg) are excluded •Participants negative for hepatitis B surface antibody (anti-HBs) but positive for hepatitis B core antibody (anti-HBc), regardless of their HBsAg status or HBV DNA results, are excluded •Participants who test positive for anti-HBc (negative HBsAg status) and positive for anti-HBs (indicating past and/or current evidence of immunity to HBV) are immune to HBV and are not excluded., Participants with HCV co-infection are eligible if: liver enzymes meet entry criteria; there is no anticipated requirement for concomitant HCV treatment with potential adverse drug interactions, and HCV disease has undergone appropriate work-up and is not advanced or associated with cirrhosis. Additional information e.g., imaging,
研究者
相似试验
进行中（未招募）
1 期
A clinical research study to evaluate the safety of changing from Flolan to a new drug called Epoprostenol-Actelion in patients suffering from pulmonary arterial hypertensioPulmonary Arterial HypertensionEUCTR2010-018322-40-BEACTELION Pharmaceuticals Ltd40
进行中（未招募）
1 期
A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2Pulmonary Arterial HypertensionEUCTR2010-018322-40-FRACTELION Pharmaceuticals Ltd41
进行中（未招募）
不适用
A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertension - EPITOME-2Pulmonary Arterial HypertensionMedDRA version: 12.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2010-018322-40-NLACTELION Pharmaceuticals Ltd35
已完成
3 期
A Multicenter, Single-arm, Open-label, Phase 3b Study to Assess the Effects of Switching From Flolan® to ACT-385781A in Patients with Pulmonary Arterial Hypertensio10037454Pulmonary arterial hypertensionNL-OMON36699Actelion Pharmaceuticals5
进行中（未招募）
不适用
Study of the drug macitentan in patients with pulmonary arterial hypertension in order to test the French, Italian, and Spanish translations of a patient questionnaire called PAH-SYMPACT.Pulmonary arterial hypertensionHipertensión arterial pulmonarMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2013-003462-14-ESACTELION Pharmaceuticals Ltd.160